AstraZeneca PLC (AZN)
NASDAQ: AZN · IEX Real-Time Price · USD
68.36
-0.17 (-0.25%)
At close: Apr 18, 2024, 4:00 PM
69.05
+0.69 (1.01%)
After-hours: Apr 18, 2024, 7:58 PM EDT
AstraZeneca Employees
AstraZeneca had 89,900 employees on December 31, 2023. The number of employees increased by 6,400 or 7.66% compared to the previous year.
Employees
89,900
Change (1Y)
6,400
Growth (1Y)
7.66%
Revenue / Employee
$509,577
Profits / Employee
$66,240
Market Cap
211.90B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
Dec 31, 2013 | 51,500 | -200 | -0.39% |
Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
Dec 31, 2007 | 67,400 | 600 | 0.90% |
Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
Pfizer | 88,000 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
AZN News
- 2 days ago - Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates. - Market Watch
- 2 days ago - Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials - Business Wire
- 2 days ago - IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial - Business Wire
- 6 days ago - No Evidence Linking Ozempic And Suicidal Thoughts, EU Says - Forbes
- 7 days ago - FASENRA approved for treatment of children aged 6 to 11 with severe asthma - Business Wire
- 8 days ago - AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM - Reuters
- 9 days ago - Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board - Accesswire
- 9 days ago - Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven. - Barrons